Waters Corporation WAT
433.54
3.24
0.75%
as of 25 Sep
- Market cap
- $42.3B
- P/E
- 108×
Follow WAT
Indexes
indicate stock being part of an index,
Insider Buys
alert about insiders buying in the last 12 month
Waters Corporation (WAT) EBITDA
Waters Corporation's EBITDA for fiscal 2025 was $1.0B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $942.8M. Over the past ten years it has ranged from $657.4M (fiscal 2015) to $1.0B (fiscal 2024); the current reading is higher than 91% of that period. Waters Corporation ranks 10th of 52 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Annual
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $1.0B | (0.92%) |
| FY2024 | $1.0B | 3.52% |
| FY2023 | $983.6M | (2.02%) |
| FY2022 | $1.0B | 5.29% |
| FY2021 | $953.4M | 23.68% |
| FY2020 | $770.9M | (5.27%) |
| FY2019 | $813.8M | (4.06%) |
| FY2018 | $848.2M | 10.41% |
| FY2017 | $768.2M | 6.47% |
| FY2016 | $721.5M | 9.74% |
Quarterly
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $215.0M | 34.38% |
| Mar 2026 | $160.0M | (50.47%) |
| Dec 2025 | $323.0M | 31.95% |
| Sep 2025 | $244.8M | 2.43% |
| 42 more quarters | Free account |
Against its own ten years
Low $657.4M
High $1.0B
Ten-year median
$848.2M
Current reading's percentile
91
EBITDA against peers
| Company | EBITDA |
|---|---|
| IQV IQVIA Holdings Inc. compare | $3.4B |
| DGX Quest Diagnostics Incorporated compare | $2.2B |
| A Agilent Technologies, Inc. compare | $1.9B |
| IDXX IDEXX Laboratories, Inc. compare | $1.6B |
| MTD Mettler-Toledo International, Inc. compare | $1.3B |
| ILMN Illumina, Inc. compare | $1.2B |
| WAT Waters Corporation | $942.8M |
| NTRA Natera, Inc. compare | −$223.9M |
| GH Guardant Health, Inc. compare | −$444.9M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on WAT
- Revenue
- Net income
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement